Over the past decade, the treatment of multiple myeloma has been revolutionized by new drug approvals. Specifically, during the past 12 years, 16 treatments have been approved, including 7 new treatments in 2015 alone. “These advances have
Matthew Mei and George Somlo
Over the past decades significant therapeutic advances have been made in the treatment of multiple myeloma (MM). A population-based study of 45,595 patients showed substantial incremental increases in myeloma-specific survival in patients younger
Jean-Luc Harousseau
Edited by Kerrin G. Robinson
. References 1 Attal M Harousseau JL Stoppa AM . A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma . N Engl J Med 1996 ; 335 : 91 – 97 . 2 Child JA Morgan GJ Davies FE . High
Shaji K. Kumar, Natalie S. Callander, Kehinde Adekola, Larry Anderson, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Malin Hultcrantz, Sarah Larson, Michaela Liedtke, Thomas Martin, James Omel, Kenneth Shain, Douglas Sborov, Keith Stockerl-Goldstein, Donna Weber, Jennifer Keller and Rashmi Kumar
Overview Multiple myeloma (MM) accounts for about 1.8% of all cancers and 18% of hematologic malignancies in the United States. 1 MM is most frequently diagnosed among people aged 65 to 74 years, with the median age being 69 years. 2 The American
Presenter : Jens Hillengass
Despite significant developments in diagnosis and treatment, multiple myeloma (MM) remains incurable in most patients, and median survival is only 6 to 8 years. As patients continue to live longer with this disease, however, quality of life becomes
Ang Li, Qian Wu, Suhong Luo, Greg S. Warnick, Neil A. Zakai, Edward N. Libby, Brian F. Gage, David A. Garcia, Gary H. Lyman and Kristen M. Sanfilippo
Background Multiple myeloma (MM) is associated with a high risk of venous thromboembolism (VTE), especially when using treatment regimens containing immunomodulatory drugs (IMiDs; eg, lenalidomide or thalidomide). 1 Initial trials of IMiDs without
Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Ammar Ashfaq, Qian Zhang and Mishal Shaukat
Background: Multiple Myeloma(MM) has a variable response rate to different chemotherapies. We sought to determine Elotuzumab efficacy by assessing 50%, 90%, and 100% decrease in the M protein levels termed as partial response (PR), very good
Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Robert L. Schlossman, Teru Hideshima, Dharminder Chauhan, Nicole A. Carreau, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson and Paul G. Richardson
Cancer ; 2008 : 200 – 213 . 2 Jemal A Siegel R Ward E . Cancer Statistics, 2009 . CA Cancer J Clin 2009 ; 59 : 225 – 249 . 3 Kumar SK Rajkumar SV Dispenzieri A . Improved survival in multiple myeloma and the impact of novel
Shaji K. Kumar
Shaji K. Kumar, MD, Professor of Medicine, Mayo Clinic Cancer Center, reviewed the significant changes in the therapeutic options and understanding of the biology of multiple myeloma (MM) at the NCCN 22nd Annual Conference. “The first step in
Paul G. Richardson, Teru Hideshima, Constantine Mitsiades and Kenneth C. Anderson
This paper was supported in part by grants: NIH SPORE IP50 CA10070-01, P0-1 78378, and R0-1 50947; the Doris Duke Distinguished Clinical Research Scientist Award; and the Cure for Myeloma Research Fund. Dr. Richardson receives research support
